The interplay between HMGB1 and other AKI biomarkers, such as NGAL and KIM-1, demonstrates a time- and dose-dependent relationship, where HMGB1 rises within hours post-cisplatin exposure, while NGAL and KIM-1 show delayed peaks (Oh et al., 2017). The gene discussed is LCN2; the disease is acute kidney injury.